<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html lang="en">
<head><meta http-equiv="Content-Type" content="text/html; charset=">
<title>Town Hall Production Ticket
</title>
</head>

<body >
<h1>
<a name="_Toc508027836"></a><a name="_Toc508028065"></a><a name="_Toc508029544"></a><a name="_Toc510101371"></a><a name="_Toc510101425"></a><a name="_Toc510106494"></a><a name="_Toc515459719"></a><a name="Heading1"></a>Town Hall Production Ticket</h1>
<p><a name="_Toc510101372"></a><a name="_Toc510101426"></a><a name="_Toc510106495"></a>For registration pages and certificate pages</p>

<p>Sections highlighted in blue should be reviewed by the SD during Content Check THPT task</p>

<p>Sections highlighted in pink should be reviewed by the SD before Copyedit of the live event</p>

<p>Sections highlighted in dark yellow should be reviewed by the SD for the enduring activity</p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Who?</strong></p>
</td>
<td><p><strong>When?</strong></p>
</td>
<td><p><strong>What?</strong></p>
</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p>Rzorzi</p>
</td>
<td><p>6/6/2018</p>
</td>
<td><p>Started Prod Ticket</p>
</td>
</tr>

<tr valign="top">
<td><p>Rzorzi</p>
</td>
<td><p>6/18</p>
</td>
<td><p>Added faculty and Agenda, added disclosures</p>
</td>
</tr>

<tr valign="top">
<td><p>rzorzi</p>
</td>
<td><p>6/28/2018</p>
</td>
<td><p>Updated LO&#8217;s as per AADE&#8217;s request</p>
</td>
</tr>

<tr valign="top">
<td><p>C Magnolo</p>
</td>
<td><p>7/6/18</p>
</td>
<td><p>CE</p>
</td>
</tr>

<tr valign="top">
<td><p>rzorzi</p>
</td>
<td><p>7/6/18</p>
</td>
<td><p>Added the &#8220;upon completion&#8221; statement for LO&#8217;s</p>
</td>
</tr>

<tr valign="top">
<td><p>C Magnolo</p>
</td>
<td><p>7/6/18</p>
</td>
<td><p>CE</p>
</td>
</tr>

<tr valign="top">
<td><p>E Casey</p>
</td>
<td><p>7/6/18</p>
</td>
<td><p>CME Review of THPT</p>
</td>
</tr>

<tr valign="top">
<td><p>Rzorzi</p>
</td>
<td><p>7/23/18</p>
</td>
<td><p>Added AADE specific partner language</p>
</td>
</tr>

<tr valign="top">
<td><p>A Esposito</p>
</td>
<td><p>8/15/18</p>
</td>
<td><p>CAR/CE slides</p>
</td>
</tr>

<tr valign="top">
<td><p>E Nyarko</p>

<p>E Casey</p>
</td>
<td><p>8/17/18</p>

<p>9/10/18</p>
</td>
<td><p>CME, CPE Review</p>

<p>Registered Enduring Activity with ACPE</p>
</td>
</tr>

<tr valign="top">
<td><p>D Lucifero</p>

<p>A Bernard</p>
</td>
<td><p>9/16/18</p>

<p>9/18/18</p>
</td>
<td><p>CE</p>

<p>CNE and CPE review </p>
</td>
</tr>

</table>
<p></p>
<h1>
<a name="HandoffNotes"></a><a name="_Toc515459720"></a><a name="Heading50"></a>Handoff Notes and Reminders</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>To Scientific Directors</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To Copyeditors</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To Production/Studio &#953;</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To CME Department</strong></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<p></p>

<p>Contents</p>
<h1>
<a name="_Toc515459721"></a><a name="Heading98"></a>General Event Information</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Destination URL: </strong></p>

<p>(eg, <a href="http://www.medscape.org/sites/townhall/public/gvhd">www.medscape.org/sites/townhall/public/gvhd</a>)</p>

<p>Note: this should <strong><em><u>not be</u></em></strong> the vanity URL</p>
</td>
<td><p>Please note the Partner (AADE) is responsible for recruitment and will not be creating a Reg page</p>

<p><strike>www.medscape.org/sites/townhall/public/</strike>insert-keywords</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Live streaming event?</strong></p>
</td>
<td><p>No</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Activity Overview </strong></p>

<p><em>(event description &#8211; 150 words maximum)</em></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<h1>
<a name="_Toc515459722"></a><a name="Heading110"></a>Registration/Overview Info</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Title:</strong></p>
</td>
<td><p>FRC Therapies: Improving Glycemic Lowering While Minimizing Adverse Effects</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Subtitle:</strong></p>

<p><strong>*Title + subtitle = 100 characters max, inc. spaces*</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Teaser (140 characters max incl. spaces)</strong></p>
</td>
<td><p>Experts in diabetes discuss realistic case studies to demonstrate the role of fixed-ratio combination basal insulin plus GLP-1 RA.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Location/map info:</strong></p>

<p><strong>(City, State &#8211; Venue, Room)</strong></p>
</td>
<td><p>Baltimore, Maryland</p>

<p>Hilton Baltimore, 401 West Pratt Street, Key Ballroom</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Date &amp; Time:</strong></p>
</td>
<td><p>Saturday, August 18, 2018</p>

<p>5:30 PM &#8211; 7:30 PM </p>
</td>
</tr>

</table>
<h1>
<a name="_Toc515459723"></a><a name="Heading126"></a>Speakers/Program Info/Faculty information/Disclosures</h1>
<p><strong>*Disclosures are not to be used for the registration page*</strong></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Speakers</strong></p>

<p><em>Names, title, affiliations </em></p>

<p><em>Disclosures </em></p>

<p>Disclosures not to be used for the registration page, only for the certificate and enduring page. Medscape staff disclosure statement to be included wherever faculty disclosures are listed (ie, print agenda and array).</p>

<p><strong>eg,</strong></p>

<p>Moderator</p>

<p>Aldo P. Maggioni, MD</p>

<p>Director </p>

<p>Research Center of Italian Association of Hospital Cardiologists (ANMCO) </p>

<p>Firenze, Italy</p>

<p>Disclosure: Aldo P. Maggioni, MD, has disclosed the following relevant financial relationships:</p>

<p>Served as an advisor or consultant for:...</p>

<p>Panelists</p>

<p>Clyde W. Yancy, MD, MSc</p>

<p>Magerstadt Professor of Medicine</p>

<p>Chief</p>

<p>Division of Cardiology </p>

<p>Northwestern University Feinberg School of Medicine</p>

<p>Chicago, Illinois, United States</p>

<p>Disclosure: Clyde W. Yancy, MD, MSc, has disclosed the following relevant financial relationships:</p>

<p>Served as an advisor or consultant for:...</p>
</td>
<td>
    
<p><strong>Chair </strong></p>

<p><strong>Davida F. Kruger, MSN, APN-BC, BC-ADM</strong></p>

<p>Nurse Practitioner</p>

<p>Henry Ford Health System</p>

<p>Detroit, Michigan</p>

<p>Disclosure: Davida F. Kruger, MSN, APN-BC, BC-ADM, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Abbott Laboratories; Eli Lilly and Company; Dexcom, Inc.; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Novo Nordisk A/S; Sanofi Aventis</p>

<p>&#9746; Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Dexcom, Inc.; Eli Lilly and Company; Insulet; Janssen Pharmaceuticals; Lilly Diabetes; Novo Nordisk A/S; Valeritas, Inc. </p>

<p>&#9746; Received grants for clinical research from: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Dexcom, Inc.; Eli Lilly and Company; Lexicon Pharmaceuticals, Inc.; Novo Nordisk A/S</p>

<p>&#9746; Owns stock, stock options, or bonds from: Dexcom, Inc.</p>

<p>Davida Kruger does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.</p>

<p>Davida Kruger does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.</p>

<p><strong>Faculty </strong></p>

<p><strong>Susan Cornell, PharmD, CDE</strong></p>

<p>Associate Professor of Pharmacy Practice</p>

<p>Associate Director of Experiential Education</p>

<p>Midwestern University Chicago College of Pharmacy</p>

<p>Downers Grove, Illinois</p>

<p>Disclosure: Susan Cornell, PharmD, CDE, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Novo Nordisk</p>

<p>&#9746; Served as a speaker or a member of a speakers bureau for: Novo Nordisk</p>

<p>Susan Cornell does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.</p>

<p>Susan Cornell does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.</p>

<p><strong>Joshua J. Neumiller, PharmD, CDE</strong></p>

<p>Associate Professor of Pharmacotherapy</p>

<p>Vice Chair</p>

<p>Washington State University</p>

<p>Spokane, Washington</p>

<p>Disclosure: Joshua J. Neumiller, PharmD, CDE, has disclosed no relevant financial relationships. </p>

<p>Joshua Neumiller does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.</p>

<p>Joshua Neumiller does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United.</p>

<p><strong>Curtis Triplitt, PharmD, CDE</strong></p>

<p>Associate Clinical Professor</p>

<p>Department of Medicine/Diabetes</p>

<p>University of Texas Health Science Center at San Antonio</p>

<p>Associate Director, Research</p>

<p>Texas Diabetes Institute </p>

<p>San Antonio, Texas</p>

<p>Disclosure: Curtiss Triplitt, PharmD, CDE, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Abbott Laboratories; Merck</p>

<p>&#9746; Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc; Lilly </p>

<p>Curtis Triplitt does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.</p>

<p>Curtis Triplitt does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.</p>

<p>Medscape, LLC staff have disclosed that they have no relevant financial relationships. </p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Program Details</strong></p>

<p><strong>***A start and end time for the overall event are required - specific start times for each section are optional, if available. Please use 24-hour clock for international programs***</strong></p>

<p><strong>eg,</strong></p>

<p>October 31, 2017  </p>

<p>5:30 AM</p>

<p>Breakfast &amp; Registration</p>

<p>6:00 AM</p>

<p>Presentation</p>

<p>6:30 AM</p>

<p>Welcome and Introductions</p>

<p>Marin H. Kollef, MD</p>

<p>7:00 AM</p>

<p>Respiratory Failure and Ventilator-Associated Pneumonia: A Critical Problem For Critical Care</p>

<p>Andrew F. Shorr, MD</p>

<p>7:30 AM</p>

<p>Treating Gram-Negative Pneumonia Today: Challenges and Considerations</p>

<p>Lee E. Morrow, MD</p>

<p>8:00 AM</p>

<p>Treating Gram-Negative Pneumonia Tomorrow: Inhaled Antibiotics</p>

<p>Marin H. Kollef, MD</p>

<p>8:30 AM</p>

<p>Antimicrobial Stewardship</p>

<p>Richard G. Wunderink, MD</p>

<p>9:00 AM</p>

<p>Closing Remarks</p>

<p>Marin H. Kollef, MD</p>

<p>9:30 AM</p>

<p>Question &amp; Answer</p>
</td>
<td><p>August 18, 2018</p>

<p>5:30 PM</p>

<p>Dinner and Registration</p>

<p>6:00 PM</p>

<p>Welcome and Introduction </p>

<p>Davida F. Kruger, MSN, APN-BC, BC-ADM</p>

<p>6:05 PM</p>

<p>Clinical Inertia Explored</p>

<p>Susan Cornell, PharmD, CDE</p>

<p>6:15 PM</p>

<p>What Is FRC Therapy? </p>

<p>Joshua J. Neumiller, PharmD, CDE</p>

<p>6:35 PM</p>

<p>Clinical Practice Case Challenges </p>

<p>Susan Cornell, PharmD, CDE</p>

<p>Joshua J. Neumiller, PharmD, CDE</p>

<p>Curtis Triplitt, PharmD, CDE</p>

<p>7:15 PM</p>

<p>Post-Assessment and Question &amp; Answer </p>

<p>Davida F. Kruger, MSN, APN-BC, BC-ADM</p>

<p><strong> </strong></p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

</table>
<h1>
<a name="_Toc515459724"></a><a name="Heading283"></a>Activity Information</h1>
<h2>
<a name="_Toc515459725"></a><a name="Heading284"></a>Left-side Content</h2>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Target Audience</strong></p>

<p><strong>(use the applicable statement)</strong></p>
</td>
<td><p>This activity is intended for nurses, nurse pratitioners, pharmacists, certified diabetes educators, and dietitians.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Goal Statement</strong></p>
</td>
<td><p>The goal of this program is to increase awareness of the clinical properties (eg, mechanisms of action, safety, and efficacy) and proper use of currently available injectable fixed-ratio combinations (FRCs) for the treatment of type 2 diabetes (T2D).</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Learning Objectives and KMI Map</strong></p>

<p>Learning objectives are needed for registration page, print materials, and certificate page. KMI map is for internal CME review of the enduring activity only.</p>
</td>
<td><p>Upon completion of this activity, participants will be able to:</p>

<p><strong>Question type answering this objective</strong></p>

<p><strong>Question #</strong></p>

<p>&#8226;	Describe the safety and efficacy data for new injectable FRC therapies</p>

<p>Posttest</p>

<p>1</p>

<p>&#8226;	Recognize the clinical use of new FRC therapies </p>

<p>Posttest</p>

<p>2</p>

<p>&#8226;	Demonstrate the effective use of new FRC therapies</p>

<p>Posttest</p>

<p>3</p>

<p>&#8226;	Discuss patient education related to FRC therapy</p>

<p>Posttest</p>

<p>4</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Association Disclaimer Statement (optional)</strong></p>

<p><em>(eg, Disclaimer: The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Industry Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program.)</em></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<h2>
<a name="_Toc515459726"></a><a name="Heading323"></a>Right-side Content</h2>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Credit Available</strong></p>

<p><strong>eg,</strong></p>

<p><strong>For Physicians</strong></p>

<p>Medscape, LLC designates this live activity for a maximum of X.X <em>AMA PRA Category 1 Credits</em>&#8482;. Physicians should claim only the credit commensurate with the extent of their participation in the activity.</p>
</td>
<td><p>For Nurses</p>

<p>Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 1.0 contact hours are in the area of pharmacology.</p>

<p>For Pharmacists</p>

<p>Medscape designates this continuing education activity for 1.0 contact hour(s) (0.01 CEUs) (Universal Activity Number: JA0007105-0000-18-208-H01-P)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Accreditation Statement</strong></p>

<p><strong>eg,</strong></p>

<p>Standard statement:</p>

<p><img height="34" width="150" src="Diab%20THEnd%20Kruger%20258079-05%20v400.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v400.jpg" border="0" ></p>

<p><img height="95" width="150" src="Diab%20THEnd%20Kruger%20258079-05%20v401.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v401.jpg" border="0" ></p>

<p>In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.</p>
</td>
<td><p><img height="34" width="150" src="Diab%20THEnd%20Kruger%20258079-05%20v400.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v400.jpg" border="0" ></p>

<p><img height="95" width="150" src="Diab%20THEnd%20Kruger%20258079-05%20v401.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v401.jpg" border="0" ></p>

<p>In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.</p>
</td>
</tr>

</table>
<h1>
<a name="_Toc515459727"></a><a name="Heading354"></a>Add to Calendar info</h1>
<p>These items are standard unless an exception is required. <strong>Notes in angle brackets are for coders. In cases where an exception is required, PM to delete notes in angle brackets and enter custom text.</strong></p>

<p>Subject: Medscape Live Event: Basal Insulin in the Modern Era: The CDE&#8217;s Role in Improving Utilization and Patient Outcomes</p>

<p>Location (room, address, venue, city, state, etc.): Hilton Baltimore, 01 West Pratt Street, Baltimore, Maryland, Key Ballroom</p>

<p>Start time: 6:00</p>

<p>End time: 8:00</p>

<p>Message: In this symposium, clinicians who treat patients with diabetes discuss ways to improve insulin initiation and strategies to transition patients to therapies that are flexible, simple, and convenient. Please join us for this Medscape Live event. </p>
<h1>
<a name="_Toc515459728"></a><a name="Heading361"></a>Supporter/Partner</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Supporter information </strong><em>(eg, &#8220;Supported by an independent educational grant from XXX&#8221;)</em></p>
</td>
<td><p>Supported by an independent educational grant from Sanofi US</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Supporter badge (for cert page and enduring page)</strong></p>

<p><strong>OUS programs also require a logo &#8211; see below</strong></p>
</td>
<td><p><img height="70" width="300" src="Diab%20THEnd%20Kruger%20258079-05%20v402.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v402.jpg" border="0" ></p>
</td>
</tr>

<tr valign="top">
<td><p><strong>For registration page: Supporter Logo (required for OUS only &#8211; this should be an image of the logo only, not a badge containing the &#8220;Supported by an...&#8221; language)</strong> </p>

<p><strong>For logos, check the Box directory for an existing file and include logo or link </strong>(<a href="https://webmd.app.box.com/files/0/f/3032075757/CME-Supporter-Badges-Logos-current">https://webmd.app.box.com/files/0/f/3032075757/CME-Supporter-Badges-Logos-current</a><a href="">)</a>. </p>

<p><strong>For OUS: If no logo badge is available on Box, please request the appropriate logo from the project team in vector format (.EPS, .AI, .SVG), and create an issue within WF for Edu Design to create. </strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Partner Statement (if applicable &#8211; edit as needed)</strong></p>
</td>
<td><p>This activity is joint-provided by the American Association of Diabetes Educators and Medscape Education</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Partner Logo (if applicable)</strong></p>
</td>
<td><p><img height="173" width="292" src="Diab%20THEnd%20Kruger%20258079-05%20v403.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v403.jpg" border="0" ></p>
</td>
</tr>

</table>
<h1>
<a name="_Toc515459729"></a><a name="Heading376"></a>Print/Collateral/Other information</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Event Information (for print)</strong></p>

<p><strong>Format:</strong></p>

<p>Date:</p>

<p>Registration (and possibly meal):</p>

<p>Presentation:</p>

<p>Location:</p>

<p>Room:</p>
</td>
<td><p>Live Town Hall</p>

<p>Date: Saturday August 18, 2018</p>

<p>Registration and Dinner: 6:00 PM</p>

<p>Presentation: 6:30 PM &#8211; 8:00 PM</p>

<p>Location: Hilton Baltimore, 401 West Pratt Street, Baltimore, Maryland</p>

<p>Room: Key Ballroom</p>
</td>
</tr>

</table>
<h1>
<a name="_Toc515459730"></a><a name="Heading394"></a>Design Information</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>What is your image recommendation?</strong></p>

<p><em>Write a brief description of a recommended image concept or theme. </em></p>
</td>
<td><p>Repurposing design from 233157.1</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Do you have images related to the concept to use as a guide? </strong></p>

<p>If <strong>yes</strong>, please provide the image resource(s) for concept direction.</p>

<p><em>(Note: due to usage requirements, some images may be unavailable for use)</em></p>

<p><strong>Resources:</strong></p>

<p><a href="http://shutterstock.com">shutterstock.com</a></p>

<p><a href="http://sciencesource.com">sciencesource.com</a></p>

<p>If <strong>no</strong>, please define desired concepts or description of the topic are acceptable.</p>

<p><em>(Ex. molecule, cell, doctor with patient, gears, rash)</em></p>

<p><strong>Town Hall Image Selection Guide:</strong></p>

<p><a href="https://webmd.box.com/v/TH-image-selection-guide">https://webmd.box.com/v/TH-image-selection-guide</a></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Are there any visual concepts or images to avoid?</strong></p>

<p><em>(Ex. cells, needles, pills)</em></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Are there any color(s) to avoid? </strong></p>

<p><em>(Ex. supporter or medication colors)</em></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<p><a name="_Toc510101383"></a><a name="_Toc510101437"></a><a name="_Toc510106506"></a><img height="0" width="295" src="Diab%20THEnd%20Kruger%20258079-05%20v404.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v404.jpg" border="0" ></p>
<h1>
<a name="_Toc515459731"></a><a name="Heading416"></a>CME info</h1>
<h2>
<a name="_Toc515459732"></a><a name="Heading417"></a>Additional Credit information</h2>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Educational Design &#953;</strong></p>
</td>
<td><p>&#9746; Competence &#953;</p>
</td>
<td><p>&#9744; Performance &#953;</p>
</td>
<td><p>&#9744; Patient Outcomes &#953;</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Core Competencies &#953;</strong></p>
</td>
<td><p>&#9746; Patient care and procedural skills</p>
</td>
<td><p>&#9746; Medical knowledge</p>
</td>
<td><p>&#9744; Practice-based learning and improvement </p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td><p>&#9744; Interpersonal &amp; communication skills</p>
</td>
<td><p>&#9744; Professionalism</p>
</td>
<td><p>&#9744; Systems-based practice</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>IPCE Competencies &#953;</strong></p>
</td>
<td><p>&#9744; Interprofessional Education (IPCE)</p>
</td>
<td><p>&#9744; Roles and Responsibilities</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td><p>&#9744; Interprofessional Communication</p>
</td>
<td><p>&#9744; Teamwork &#953;</p>
</td>
<td><p>&#9744; Values and Ethics</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Activity Length &#953;:</strong></p>
</td>
<td><p>1 hour</p>
</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><a name="_Toc510101386"></a><a name="_Toc510101440"></a><a name="_Toc510106509"></a><strong>Is there a collection page?</strong></p>
</td>
<td><p>&#9744; No</p>
</td>
<td><p>&#9746; Yes; <strong>what type?</strong> Clinical Advances; <strong>provide name and URL:</strong> ACS and Beyond: Worldwide Perspectives in Acute and Secondary Prevention    https://www.medscape.org/sites/advances/acs-and-beyond</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>If &#8216;Clinical Advances,&#8217; which bucket does the content go in?</strong> (Click here to enter...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Add to other publications or pages?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes; add <strong>URL(s) and bucket name(s) &#953;</strong>: (Click here to enter...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Geotargets &#953;</strong></p>
</td>
<td><p><strong>1:</strong> (Choose a geotarget...)</p>
</td>
<td><p><strong>2:</strong> (Choose a geotarget...)</p>
</td>
<td><p><strong>3:</strong> (Choose a geotarget...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Peer review required?</strong></p>
</td>
<td><p>No, Partner will peer review</p>
</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

</table>
<h1>
<a name="_Toc515459733"></a><a name="Heading456"></a>General Information</h1>
<p></p>
<h1>
<a name="_Toc515459734"></a><a name="Heading458"></a>Product-Specific Information and Add-ons</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Is there an Outcomes study?</strong></p>
</td>
<td><p>No</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there a second Outcomes study?</strong></p>
</td>
<td><p>(Select response...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there a Medscape Discuss or Discuss Lite?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Medscape Discuss</p>
</td>
<td><p>&#9744; Medscape Discuss Lite</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there an associated HCP Perspective?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is this program associated with a Patient Education Program or Destination Page?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Provide server path for Prescription to Learn PDF:</strong></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<h1>
<a name="_Toc515459735"></a><a name="Heading475"></a>Town Hall Statement and Posting Date</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Event Statement</strong></p>
</td>
<td><p>No certificate page</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Posting Date</strong></p>
</td>
<td><p><strong>August 18, 2018</strong></p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Expiration Date</strong></p>
</td>
<td><p><strong>September 22, 2018</strong></p>
</td>
</tr>

</table>
<p><img height="0" width="295" src="Diab%20THEnd%20Kruger%20258079-05%20v405.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v405.jpg" border="0" ></p>
<h1>
<a name="_Toc515459736"></a><a name="Heading483"></a>Additional Disclosures</h1>
<p></p>
<h3>
<a name="_Toc515459737"></a><a name="Heading485"></a>SD/Editor/Writer Information and Disclosure Statements</h3>
<p></p>
<h4>
<a name="Heading487"></a>Anne G. Le, PharmD

<a name="Heading488"></a>Senior Scientific Director, Medscape, LLC

Disclosure: Anne G. Le, PharmD, has disclosed no relevant financial relationships.</h4>
<p></p>
<h3>
<a name="_Toc515459738"></a><a name="Heading490"></a>Additional Planners/Reviewers Information and Disclosure Statements

<a name="Heading491"></a>CE Reviewer / Nurse Planner

<a name="Heading492"></a>Amy Bernard, MS, BSN, RN-BC, CHCP</h3>
<p>Lead Nurse Planner, Medscape, LLC</p>

<p>Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.</p>

<p>***Please delete the unneeded CME reviewer below, or add a custom entry for a different reviewer***</p>

<p><a name="_Toc510101391"></a><a name="_Toc510101445"></a><a name="_Toc510106514"></a><img height="0" width="295" src="Diab%20THEnd%20Kruger%20258079-05%20v405.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v405.jpg" border="0" ></p>
<h1>
<a name="_Toc515459739"></a><a name="Heading500"></a>Related links</h1>
<p><em>List 3 to 5 related links to </em><strong><em>content</em> &#953;</strong><em> on medscape.org and the titles of the activities to be added to this activity.</em></p>

<p>Cardiovascular Effects of Using GLP-1-Based Therapies for Type 2 Diabetes Mellitus</p>

<p><a href="https://www.medscape.org/viewarticle/890941">https://www.medscape.org/viewarticle/890941</a> </p>

<p>Working as a Team for Cardiovascular Risk Reduction in Patients With T2D</p>

<p><a href="https://www.medscape.org/viewarticle/894749">https://www.medscape.org/viewarticle/894749</a></p>

<p>ADA Recommends How to Improve Insulin Access, Affordability</p>

<p><a href="https://www.medscape.org/viewarticle/897667">https://www.medscape.org/viewarticle/897667</a> </p>

<p><a name="_Toc510101393"></a><a name="_Toc510101447"></a><a name="_Toc510106516"></a><img height="0" width="295" src="Diab%20THEnd%20Kruger%20258079-05%20v405.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v405.jpg" border="0" ></p>
<h1>
<a name="_Toc515459740"></a><a name="Heading512"></a>Questions (fill in when appropriate, either before Live or Enduring CME review)</h1>
<p></p>
<h2>
<a name="_Toc515459741"></a><a name="Heading514"></a>CME Post-test questions</h2>
<p><strong>Question type:</strong> CME Posttest</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> A 54-year-old woman with type 2 diabetes (T2D) and a history of severe hypoglycemia and retinopathy presents to your office today for a follow-up appointment. She is not at her glycated hemoglobin (HbA<sub>1c</sub>)<sub> </sub>goal on the maximum dose of metformin and 40 units of insulin degludec, and is receptive to other options. You discuss with her the new fixed-ratio combinations (FRCs), insulin glargine/lixisenatide and insulin degludec/liraglutide for the treatment of T2D. </p>

<p><strong>Question 1:</strong> Since she is already on degludec, the combination degludec/liraglutide may be the most appropriate option. 'What different effects can be expected from this combination compared with its components alone?</p>

<p>&#8226;	More nausea</p>

<p>&#8226;	More weight gain</p>

<p>&#8226;	Greater HbA<sub>1c </sub>reduction </p>

<p>&#8226;	Comparable HbA<sub>1c </sub>reduction</p>

<p>Answer explanation: In the DUAL clinical program evaluating the safety and efficacy of insulin degludec/liraglutide, 3 trials including 1393 adults with uncontrolled T2D were switched to the combination, which demonstrated significant reductions in HbA<sub>1c </sub>from a baseline of greater than 1%. The common adverse events were reportedly nausea and diarrhea. Pros of this combination include a once daily injection, more HbA<sub>1c </sub>reduction vs its components, as well as mitigation of weight gain and lower risk of hypoglycemia vs its components.</p>




<p><strong>Question type:</strong> CME Posttest</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> </p>

<p><strong>Question 2:</strong> Another option is insulin glargine/lixisenatide. How effective is this combination compared with its components alone?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#8226;	Comparable HbA<sub>1c </sub>reduction</p>

<p>&#8226;	Greater postprandial glucose excursions</p>

<p>&#8226;	More nausea</p>

<p>&#8226;	More weight gain</p>

<p>Answer explanation: The LixiLan clinical program evaluated the safety and efficacy of insulin glargine/lixisenatide vs its components in people with T2D inadequately controlled on basal insulin with or without oral agents. The combination reduced HbA<sub>1c </sub>greater than its components. Its effect on fasting plasma glucose (FPG) was minimal, but postprandial glucose excursions were significantly improved compared with insulin glargine. Weight reduction was minimal with the combination, as the weight gain caused by insulin glargine is mitigated by the weight reduction of lixisenatide. At lower HbA<sub>1c </sub>values, the contribution of postprandial glucose is greater.</p>



<p><strong>Question type:</strong> CME Posttest</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> </p>

<p><strong>Question 3:</strong> What is the appropriate starting dose for insulin glargine/lixisenatide for a person with T2D taking 25 units of basal insulin glargine?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#8226;	10 units</p>

<p>&#8226;	15 units</p>

<p>&#8226;	16 units</p>

<p>&#8226;	0.2 units/kg</p>

<p>Answer explanation: The recommended dose for patients inadequately controlled on &lt; 30 units of basal insulin or on lixisenatide is 15 units of insulin glargine and 5 &#956;g of lixisenatide administered subcutaneously once daily. For those inadequately controlled on 30 to 60 units of basal insulin, the dose is 30 units of insulin glargine and 10 &#956;g of lixisenatide. The dosage may be titrated up or down by 2 to 4 units every week based on response and until the patient achieves the desired FPG. </p>




<p><strong>Question type:</strong> CME Posttest</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> </p>

<p><strong>Question 4:</strong> Because of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) component, what should people who are on an injectable FRC know that they should do? </p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#8226;	Stop or decrease food intake when they experience a feeling of fullness</p>

<p>&#8226;	Take the medication on an empty stomach</p>

<p>&#8226;	Take the medication with food</p>

<p>&#8226;	Take the medication with a glass of milk</p>

<p>Answer explanation: People should be educated that the most common adverse event of GLP-1 RAs are nausea and vomiting, and that the GLP-1 RA component may promote a feeling of satiety. Thus, they should stop eating when they feel full.</p>
<h2>
<a name="_Toc515459742"></a><a name="Heading555"></a>Intra-activity questions (configure grid as needed)</h2>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Y/N</strong></p>
</td>
<td><p><strong>Feature</strong></p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Required</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Poll Results</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Right/Wrong</p>
</td>
</tr>

<tr valign="top">
<td><p>N</p>
</td>
<td><p>Should users be able to select more than one answer?</p>
</td>
</tr>

</table>
<p><strong>Question 1:</strong> Based on RL's presentation, which of the following medication changes would you recommend at this time?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#8226;	Uptitrate his insulin glargine</p>

<p>&#8226;	Add a sulfonylurea</p>

<p>&#8226;	Add a GLP-1 RA</p>

<p>&#8226;	Change him to a premixed insulin product</p>



<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Y/N</strong></p>
</td>
<td><p><strong>Feature</strong></p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Required</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Poll Results</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Right/Wrong</p>
</td>
</tr>

<tr valign="top">
<td><p>N</p>
</td>
<td><p>Should users be able to select more than one answer?</p>
</td>
</tr>

</table>
<p><strong>Question 2:</strong> Which of the following choices for treatment could be recommended by current FDA labeling?</p>

<p><strong>Answer choices &#953;:</strong> </p>

<p>&#8226;	Add insulin degludec/liraglutide daily</p>

<p>&#8226;	Add lixisenatide/insulin glargine daily</p>

<p>&#8226;	Add liraglutide daily</p>

<p>&#8226;	Add insulin glargine daily</p>

<p>&#8226;	Both adding liraglutide daily and insulin glargine daily are within FDA labeling</p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Y/N</strong></p>
</td>
<td><p><strong>Feature</strong></p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Required</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Poll Results</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Right/Wrong</p>
</td>
</tr>

<tr valign="top">
<td><p>N</p>
</td>
<td><p>Should users be able to select more than one answer?</p>
</td>
</tr>

</table>


<p><strong>Question 3:</strong> Which of the following is the most appropriate therapeutic option for MT?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#8226;	Add NPH insulin</p>

<p>&#8226;	Add a basal insulin</p>

<p>&#8226;	Switch to an injectable FRC product</p>

<p>&#8226;	Add a rapid-acting insulin</p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Y/N</strong></p>
</td>
<td><p><strong>Feature</strong></p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Required</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Poll Results</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Right/Wrong</p>
</td>
</tr>

<tr valign="top">
<td><p>N</p>
</td>
<td><p>Should users be able to select more than one answer?</p>
</td>
</tr>

</table>
<p><strong>Question 4:</strong> What is the appropriate starting dose for insulin degludec/liraglutide?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#8226;	10 units</p>

<p>&#8226;	15 units</p>

<p>&#8226;	16 units</p>

<p>&#8226;	30 units</p>

<p><img height="0" width="295" src="Diab%20THEnd%20Kruger%20258079-05%20v405.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v405.jpg" border="0" ></p>
<h1>
<a name="_Toc515459752"></a><a name="Heading625"></a>Abbreviations</h1>
<p></p>

<p>AACE = American Association of Clinical Endocrinologists</p>

<p>ACE = American College of Endocrinology</p>

<p>ADA = American Diabetes Association</p>

<p>AE = adverse event</p>

<p>ASCVD = atherosclerotic cardiovascular disease</p>

<p>BMI = body mass index</p>

<p>BP = blood pressure</p>

<p>CI = confidence interval</p>

<p>CV = cardiovascular </p>

<p>CVD = cardiovascular disease</p>

<p>eGFR = estimated glomerular filtration rate</p>

<p>FBG = fasting blood glucose</p>

<p>FPG = fasting plasma glucose</p>

<p>FRC = fixed-ratio combination</p>

<p>GI = gastrointestinal</p>

<p>GLP-1 RA = glucagon-like peptide-1 receptor agonist</p>

<p>HbA<sub>1c</sub> = glycated hemoglobin</p>

<p>HDL = high-density lipoprotein</p>

<p>HTN = hypertension</p>

<p>IDegLira = insulin degludec/liraglutide</p>

<p>iGlar = insulin glargine</p>

<p>iGlarLixi = insulin glargine/lixisenatide</p>

<p>IR = insulin resistance</p>

<p>LDL = low-density lipoprotein</p>

<p>Lixi = lixisenatide</p>

<p>LOCF = last observation carried forward</p>

<p>LS = least squares</p>

<p>Met = metformin</p>

<p>MI = myocardial infarction</p>

<p>NHANES = National Health and Nutrition Examination Survey </p>

<p>OA = osteoarthritis</p>

<p>OAD = oral antihyperglycemic drug</p>

<p>Pio = pioglitazone</p>

<p>PMH = past medical history</p>

<p>PPG = postprandial glucose</p>

<p>SCr = serum creatinine</p>

<p>SE = standard error</p>

<p>SGLT2 = sodium-glucose cotransporter 2</p>

<p>SMBG = self-monitoring of blood glucose</p>

<p>SU = sulfonylurea</p>

<p>T2D = type 2 diabetes</p>

<p>TG = triglyceride</p>

<p>UACR = urine albumin-to-creatinine ratio</p>

<p><a name="_Toc510101462"></a><a name="_Toc510106530"></a><img height="0" width="295" src="Diab%20THEnd%20Kruger%20258079-05%20v405.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v405.jpg" border="0" ></p>
<h1>
<a name="_Toc515459753"></a><a name="Heading672"></a>Transcript, chapter titles, and time codes (for enduring version only)</h1>
<p></p>

<p>&lt;&lt;insert slide 1; Chapter Title: Introduction; 00:00 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; FRC Therapies: Improving Glycemic Lowering While Minimizing Adverse Effects</strong></p>

<p>&lt;&lt;insert slide 2; 00:22 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Program</strong></p>

<p>&lt;&lt;insert slide 3; Chapter Title: Clinical Inertia Explored; 00:58 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Clinical Inertia Explored</strong></p>

<p>&lt;&lt;insert slide 4; 01:10 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; The Challenge of Glycemic Control<sup>[1]</sup></strong></p>

<p>&lt;&lt;insert slide 5; 02:28 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Why Is Glucose Control Important?<sup>[2]</sup></strong></p>

<p>&#8226;	Keeping in mind that the majority of people with type 2 diabetes (T2D) present with at least 1 complication, means that he or she has had T2D for at least a few years</p>

<p>&lt;&lt;insert slide 6; 04:12 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; &#946;-Cell Decline in Prediabetes and T2D<sup>[3]</sup></strong></p>

<p>&#8226;	By the time T2D is diagnosed, the number of &#946;-cells has declined ~80%</p>

<p>&#8226;	Some antihyperglycemic classes have an effect on &#946;-cell function</p>

<p>&lt;&lt;insert slide 7; 06:19 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Monotherapy Rarely Controls Diabetes for the Duration<sup>[4]</sup></strong></p>

<p>&#8226;	Lifestyle management is the initial therapy, but rarely is enough to control T2D</p>

<p>&lt;&lt;insert slide 8; 07:24 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Clinical Inertia Leaves Individuals Unnecessarily Exposed to Hyperglycemia<sup>[5]</sup></strong></p>

<p>&lt;&lt;insert slide 9; Chapter Title: FRC Therapy; 08:20 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; What Is FRC Therapy?</strong></p>

<p>&lt;&lt;insert slide 10; 08:30 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Antihyperglycemic Therapy in Adults With T2D<sup>[4]</sup></strong></p>

<p>&#8226;	Consider combination therapy in people with high glycated hemoglobin (HbA<sub>1c</sub>)<sub> </sub>in order to lower their HbA<sub>1c</sub></p>

<p>&lt;&lt;insert slide 11; 09:46 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Antihyperglycemic Therapy in Adults With T2D (cont)<sup>[4]</sup></strong></p>

<p>&#8226;	Certain antihyperglycemic agents now have cardiovascular (CV) outcome data to show they have beneficial effects on CV risk</p>

<p>&lt;&lt;insert slide 12; 11:48 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Consideration of Injectable Therapies<sup>[4]</sup></strong></p>

<p>&lt;&lt;insert slide 13; 13:51 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Postprandial vs Fasting Hyperglycemia on HbA<sub>1c</sub><sup>[6]</sup></strong></p>

<p>&#8226;	At lower HbA<sub>1c</sub> values, the contribution of postprandial glucose (PPG) is greater</p>

<p>&lt;&lt;insert slide 14; 14:41 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Targeting PPG Excursions<sup>[4]</sup></strong></p>

<p>&lt;&lt;insert slide 15; 14:56 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; GLP-1 RA and Prandial Insulin<sup>[4]</sup></strong></p>

<p>&lt;&lt;insert slide 16; 16:20 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; GLP-1 RA vs Bolus Insulin in People Who Have T2D With Optimized Basal Insulin<sup>[7]</sup></strong></p>

<p>&#8226;	HbA<sub>1c </sub>lowering of lispro 3 times a day and exenatide twice daily comparable</p>

<p>&#8226;	Exenatide twice daily has a greater effect on PPG</p>

<p>&#8226;	Weight gain seen with insulin lispro</p>

<p>&lt;&lt;insert slide 17; 18:24 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; GLP-1 RAs + Basal Insulin vs Basal-Bolus Insulin: A Meta-Analysis<sup>[8]</sup></strong></p>

<p>&#8226;	Glucagon-like peptide-1 receptor agonist (GLP-1 RA) compared with basal-bolus regimens: less hypoglycemic risk and weight gain</p>

<p>&lt;&lt;insert slide 18; 19:25 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; FRC Therapies: Basal + GLP-1 RA Injectables</strong></p>

<p>&lt;&lt;insert slide 19; 19:52 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Lixisenatide/Insulin Glargine FRC<sup>[9]</sup></strong></p>

<p>&#8226;	People with T2D on oral agents randomized to either lixisenatide/insulin glargine fixed-ratio combination (FRC) or the individual components by themselves (off-label)</p>

<p>&lt;&lt;insert slide 20; 21:41 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Lixisenatide/Insulin Glargine FRC (cont)<sup>[9]</sup></strong></p>

<p>&#8226;	Lixisenatide/insulin glargine FRC mitigated some of the weight gain seen with insulin glargine by itself</p>

<p>&#8226;	People tend to tolerate lixisenatide/insulin glargine FRC better than GLP-1 RA by itself</p>

<p>&lt;&lt;insert slide 21; 23:48 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Lixisenatide/Insulin Glargine FRC (cont)<sup>[10]</sup></strong></p>

<p>&lt;&lt;insert slide 22; 26:11 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Insulin Degludec/Liraglutide FRC<sup>[11]</sup></strong></p>

<p>&#8226;	People with T2D on oral agents randomized to either insulin degludec/liraglutide FRC or the individual components by themselves (off-label)</p>

<p>&lt;&lt;insert slide 23; 27:42 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Insulin Degludec/Liraglutide FRC (cont)<sup>[11]</sup></strong></p>

<p>&#8226;	Insulin degludec/liraglutide FRC mitigated some of the weight gain seen with insulin degludec by itself</p>

<p>&#8226;	People tend to tolerate insulin degludec/liraglutide FRC better than GLP-1 RA by itself</p>

<p>&lt;&lt;insert slide 24; 28:49 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Insulin Degludec/Liraglutide FRC (cont)<sup>[12]</sup></strong></p>

<p>&lt;&lt;insert slide 25; Chapter Title: Clinical Practice Case Challenges; 29:55 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Clinical Practice Case Challenges</strong></p>

<p>&lt;&lt;insert slide 26; Chapter Title: Case 1; 29:59 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 1: Targeting PPG Following Basal Insulin Optimization</strong></p>

<p>&lt;&lt;insert slide 27; 30:06 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 1: RL</strong></p>

<p>&lt;&lt;insert slide 28; 30:43 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 1 (cont)</strong></p>

<p>&lt;&lt;insert slide 29; 31:25 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 1 (cont)</strong></p>

<p>&lt;&lt;insert slide 30; 32:24 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 1 (cont)</strong></p>

<p>&lt;&lt;insert slide 31; 33:29 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 1: RL's 3-Day Blood Glucose Log</strong></p>

<p>&lt;&lt;insert slide 32; 35:17 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Summary of Glycemic Recommendations<sup>[13]</sup></strong></p>

<p>&#8226;	HbA<sub>1c</sub> &lt;7% recommended in this person with diabetes</p>

<p>&lt;&lt;insert slide 33; 35:56 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 1 (cont)</strong></p>

<p>&lt;&lt;Intra-activity question 1; 36:21 &gt;&gt; </p>

<p>&lt;&lt;insert slide 34; 36:22 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Consideration of Injectable Therapies<sup>[4]</sup></strong></p>

<p>&#8226;	Need to target PPG in this person with diabetes as his fasting blood glucose is at target</p>

<p>&lt;&lt;insert slide 35; 37:03 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Lixisenatide/Insulin Glargine FRC<sup>[10]</sup></strong></p>

<p>&lt;&lt;insert slide 36; 37:56 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 1 Summary</strong></p>

<p>&lt;&lt;insert slide 37; Chapter Title: Case 2; 40:25 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 2: FRC Therapies: Improving Glycemic Lowering While Minimizing Adverse Effects</strong></p>

<p>&lt;&lt;insert slide 38; 40:38 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 2, TH: Newly Diagnosed With T2D</strong></p>

<p>&lt;&lt;insert slide 39; 41:43 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 2 (cont)</strong></p>

<p>&lt;&lt;Intra-activity question 2; 42:43 &gt;&gt; </p>

<p>&lt;&lt;insert slide 40; 42:44 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; FRC Medications: FDA Labeling<sup>[10,12]</sup></strong></p>

<p>&lt;&lt;insert slide 41; 44:02 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Can a FRC Therapy Be Started in This Clinical Situation?</strong></p>

<p>&lt;&lt;insert slide 42; 44:11 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Major Diabetes Organizations Recommend Combination Therapy (Both Recommend Lifestyle Plus Medications)<sup>[4,14]</sup></strong></p>

<p>&lt;&lt;insert slide 43; 44:52 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Early Combination Instead of Step Therapy Initiation<sup>[15]</sup></strong></p>

<p>&#8226;	Combination therapy has been shown to help your patient get to their HbA<sub>1c</sub> goal more often</p>

<p>&lt;&lt;insert slide 44; 46:22 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; FRC Therapy With Oral Agents<sup>[9,11]</sup></strong></p>

<p>&#8226;	Robust HbA<sub>1c </sub>lowering with FRC injectables</p>

<p>&lt;&lt;insert slide 45; 47:32 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; FRC Therapy: GI Adverse Effects and Discontinuation<sup>[16]</sup></strong></p>

<p>&#8226;	Hypoglycemic risk not increased with FRC injectables vs insulin component alone</p>

<p>&lt;&lt;insert slide 46; 48:42 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 2 (cont)</strong></p>

<p>&lt;&lt;insert slide 47; 49:19 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; FRC: Clinical Trial Starting Doses<sup>[9,11]</sup></strong></p>

<p>&#8226;	Dosing in clinical trials different than recommended dosing in product prescribing information</p>

<p>&lt;&lt;insert slide 48; 50:03 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; FRC Pen Devices<sup>[10,12]</sup></strong></p>

<p>&lt;&lt;insert slide 49; 50:48 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 2 (cont)</strong></p>

<p>&#8226;	FDA approved starting dose for lixisenatide/insulin glargine is &lt;60 units/day</p>

<p>&#8226;	FDA approved starting dose for insulin degludec/liraglutide is &lt;50 units/day</p>

<p>&#8226;	FDA-approved titration schedule for lixisenatide/insulin glargine is 2 to 4 units once weekly on the basis of fasting plasma glucose (FPG)</p>

<p>&#8226;	FDA-approved titration schedule for insulin degludec/liraglutide is 2 units every 3 to 4 days on the basis of FPG </p>

<p>&lt;&lt;insert slide 50; 51:49 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Key Takeaways, Case 2</strong></p>

<p>&lt;&lt;insert slide 51; 52:46 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 2 Summary</strong></p>

<p>&lt;&lt;insert slide 52; Chapter Title: Case 3; 54:04 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 3: Switching to an FRC Injectable From a GLP-1 RA</strong></p>

<p>&lt;&lt;insert slide 53; 54:14 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 3, MT</strong></p>

<p>&lt;&lt;Intra-activity question 3; 55:39 &gt;&gt; </p>

<p>&lt;&lt;insert slide 54; 55:40 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 3 (cont)</strong></p>

<p>&lt;&lt;insert slide 55; 57:05 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 3 (cont)</strong></p>

<p>&lt;&lt;Intra-activity question 4; 58:43 &gt;&gt; </p>

<p>&lt;&lt;insert slide 56; 58:44 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 3 (cont)</strong></p>

<p>&#8226;	Individualize titration for each patient</p>

<p>&lt;&lt;insert slide 57; 1:00:50 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Case 3 Summary</strong></p>

<p>&lt;&lt;insert slide 58; Chapter Title: Thank You; 01:00:57 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Thank You</strong></p>

<p><em>This content has been condensed for improved clarity.</em></p>

<p><em>&lt;&lt;end slides&gt;&gt;</em></p>

<p><img height="0" width="295" src="Diab%20THEnd%20Kruger%20258079-05%20v405.jpg" 	alt="Diab%20THEnd%20Kruger%20258079-05%20v405.jpg" border="0" ></p>
<h1>
<a name="_Toc515459754"></a><a name="Heading889"></a>References (for enduring version only)</h1>
<p></p>

<p>1. Ali MK, Bullard KM, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. <em>N Engl J Med</em>. 2013;369:287-288. </p>

<p>2. American Association of Clinical Endocrinologists. State of diabetes complications in America. A comprehensive report issued by the American Association of Clinical Endocrinologists. Available at: http://multivu.prnewswire.com/mnr/AACE/2007/docs/Diabetes_Complications_Report.pdf. Accessed September 10, 2018.</p>

<p>3. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. <em>Diabetes</em>. 2009;58:773-795. </p>

<p>4. American Diabetes Association. Section 8. Pharmacologic approaches to glycemic treatment: <em>standards of medical care in diabetes-2018</em>. <em>Diabetes Care</em>. 2018;41(suppl 1):S73-S85.</p>

<p>5. Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. <em>Diabetes Care</em>. 2013;36:3411-3417. </p>

<p>6. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. <em>Diabetes Care</em>. 2003;26:881-885.</p>

<p>7. Diamant M, Nauck MA, Shaginian R, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. <em>Diabetes Care</em>. 2014;37:2763-2773. </p>

<p>8. Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. <em>Lancet</em>. 2014;384:2228-2234. </p>

<p>9. Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. <em>Diabetes Care</em>. 2016;39:2026-2035. </p>

<p>10. Soliqua 100/33&reg; [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2017.</p>

<p>11. Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. <em>Lancet Diabetes Endocrinol</em>. 2014;2:885-893. </p>

<p>12. Xultophy&reg; 100/3.6 [package insert]. Plainsboro, NJ: Novo Nordisk; 2016.</p>

<p>13. American Diabetes Association. Section 6. Glycemic targets: standards of medical care in diabetes-2018. <em>Diabetes Care</em>. 2018;41(suppl 1):S55-S64.</p>

<p>14. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary. <em>Endocrine Practice</em>. 2018;24:91-120.</p>

<p>15. Phung OJ, Sobieraj DM, Engel SS, et al. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. <em>Diabetes Obes Metab</em>. 2014;16:410-417. </p>

<p>16. Nuffer W, Guesnier A, Trujillo JM. A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products. <em>Ther Adv Endocrinol Metab</em>. 2018;9:69-79. </p>


</body>

</html>
